BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang GQ, Ding YP, Dong YH. Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat. 2013;20 Suppl 1:9-17. [PMID: 23458520 DOI: 10.1111/jvh.12059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Wang HJ, Jiang YF, Wang XR, Zhang ML, Gao PJ. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. World J Gastroenterol 2016; 22(18): 4529-4537 [PMID: 27182162 DOI: 10.3748/wjg.v22.i18.4529] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
2 Wei XL, Qiu MZ, Chen WW, Jin Y, Ren C, Wang F, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. J Transl Med 2013;11:249. [PMID: 24099678 DOI: 10.1186/1479-5876-11-249] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
3 Chen J, Li D. Telbivudine attenuates UUO-induced renal fibrosis via TGF-β/Smad and NF-κB signaling. Int Immunopharmacol 2018;55:1-8. [PMID: 29207359 DOI: 10.1016/j.intimp.2017.11.043] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
4 He D, Guo S, Zhu P, Tao S, Li M, Huang H, Wang J, Wang Y, Ding M. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients. Clin Microbiol Infect. 2014;20:O687-O693. [PMID: 25469947 DOI: 10.1111/1469-0691.12605] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
5 Xing T, Xu H, Cao L, Ye M. HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis. PLoS One 2017;12:e0169444. [PMID: 28107377 DOI: 10.1371/journal.pone.0169444] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
6 Koenig T, Kempf T, Schultheiss HP, Cornberg M, Bauersachs J, Schäfer A. Fulminant parvovirus B19 myocarditis after chemotherapy: full recovery after antiviral therapy with tenofovir. Clin Res Cardiol 2021. [PMID: 34669016 DOI: 10.1007/s00392-021-01955-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang ML, Zhou QL, Chen EQ, Du LY, Yan LB, Bai L, He M, Tang H. Low Ratio of Treg to Th17 Cells After 36 Weeks of Telbivudine Therapy Predict HBeAg Seroconversion. Viral Immunol 2016;29:332-42. [PMID: 27104358 DOI: 10.1089/vim.2016.0007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Singh L, Indermun S, Govender M, Kumar P, du Toit LC, Choonara YE, Pillay V. Drug Delivery Strategies for Antivirals against Hepatitis B Virus. Viruses 2018;10:E267. [PMID: 29772748 DOI: 10.3390/v10050267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
9 Lu J, Wang X, Zhu Y, Ma L, Zheng S, Hu Z, Chen X. Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. Gut Liver 2021;15:887-94. [PMID: 34446613 DOI: 10.5009/gnl21001] [Reference Citation Analysis]
10 Zhang Y, Hu P, Qi X, Ren H, Mao RC, Zhang JM. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China. Clin Microbiol Infect. 2016;22:287.e1-287.e9. [PMID: 26548508 DOI: 10.1016/j.cmi.2015.10.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
11 Ho CH, Chang TT, Chien RN. Telbivudine on IgG-associated hypergammaglobulinemia and TGF-β1 hyperactivity in hepatitis B virus-related liver cirrhosis. PLoS One 2019;14:e0225482. [PMID: 31770396 DOI: 10.1371/journal.pone.0225482] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Wu Y, Jie Y, Li X, Huang M, Li X, Shi H, Chen S, Zhang M, Ao Y, Yang F, Gao Z, Lin G, Chong Y. Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients. Clin Res Hepatol Gastroenterol 2016;40:213-20. [PMID: 26598028 DOI: 10.1016/j.clinre.2015.06.018] [Reference Citation Analysis]
13 van Bömmel F, Bartens A, Mysickova A, Hofmann J, Krüger DH, Berg T, Edelmann A. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors: van BÖMMEL ET AL. Hepatology 2015;61:66-76. [DOI: 10.1002/hep.27381] [Cited by in Crossref: 127] [Cited by in F6Publishing: 120] [Article Influence: 15.9] [Reference Citation Analysis]
14 Law S, Lee MK, Li KK, Mok CK. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B: . European Journal of Gastroenterology & Hepatology 2016;28:193-8. [DOI: 10.1097/meg.0000000000000519] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]